Biofrontera Inc. (BFRIW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Biofrontera Inc. (BFRIW) Healthcare & Pipeline Overview

Biofrontera Inc. is a U.S.-based biopharmaceutical firm specializing in commercializing dermatological treatments, including Ameluz for actinic keratosis and Xepi for impetigo. The company utilizes its proprietary photodynamic therapy system to address skin-related ailments, positioning itself within the specialty dermatology market.

What Is the Investment Thesis for BFRIW?

Biofrontera Inc. operates within the U.S. dermatological market, primarily commercializing Ameluz for actinic keratosis and Xepi for impetigo. A key value driver is the established market for Ameluz, a prescription drug utilized with the BF-RhodoLED lamp series for photodynamic therapy, addressing a significant patient population with mild-to-moderate actinic keratosis. The company's high gross margin of 82.8% indicates strong product profitability. However, the company faces substantial financial risks, highlighted by its very low market capitalization of $16.7M (specifically, $264,265 as per AI insight) and a negative profit margin of -25.7%. This financial profile necessitates close monitoring of cash flow and future financing activities. Growth catalysts could include expanded market penetration for Ameluz, potential new indications, or increased adoption of Xepi. The company's beta of 0.85 suggests lower volatility compared to the broader market, but this must be weighed against its significant financial vulnerabilities.

Based on FMP financials and quantitative analysis

BFRIW Key Highlights

Gross margin of 82.8% indicates strong profitability on product sales, exceeding many industry benchmarks.

• Profit margin of -25.7% reflects ongoing operational losses, signaling a need for improved financial performance.
• Market capitalization of $16.7M (specifically $264,265) indicates a micro-cap status, presenting significant liquidity and financial risk.
• Beta of 0.85 suggests the stock is less volatile than the overall market, potentially offering some stability in price movements.
• The company employs 92 individuals, focusing on commercialization and support for its specialized dermatological product portfolio.

Who Are BFRIW's Competitors?

BFRIW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BFRIW's Key Strengths?

Established market for Ameluz, a key product for actinic keratosis treatment.

• High gross margin of 82.8% indicates strong product-level profitability.
• Proprietary photodynamic therapy system (Ameluz with BF-RhodoLED lamp series).
• Presence in the U.S. specialty dermatology market with two commercialized products.

What Are BFRIW's Weaknesses?

Very low market capitalization ($264,265) signals significant financial risk and potential liquidity issues.

• Negative profit margin of -25.7% indicates ongoing operational losses.
• Reliance on a limited product portfolio for revenue generation.
• Potential challenges in cash flow and future financing activities.

What Could Drive BFRIW Stock Higher?

BFRIW catalyst: Potential for increased market penetration of Ameluz through enhanced sales and marketing initiatives targeting dermatological clinics across the U.S.

• Any future regulatory filings or approvals for expanded indications of Ameluz or Xepi, which could broaden their addressable patient populations.
• Continued adoption of the BF-RhodoLED lamp series by new clinics, driving recurring revenue from Ameluz sales.
• Publication of new clinical data or real-world evidence supporting the efficacy and safety of Ameluz or Xepi, potentially influencing physician prescribing habits.

What Are the Key Risks for BFRIW?

Financial-distress signal — its Altman Z-Score of -5.34 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• The company's very low market capitalization of $264,265 signals significant financial risk, including potential challenges in securing future financing or maintaining liquidity.
• A negative profit margin of -25.7% indicates that the company is currently operating at a loss, raising concerns about long-term financial sustainability without improved revenue generation or cost management.
• Intense competition within the dermatological drug market from larger pharmaceutical companies with broader product portfolios and greater financial resources.
• Dependence on the successful commercialization of a limited number of products (Ameluz and Xepi), making the company vulnerable to market shifts or competitive pressures impacting these specific treatments.
• Regulatory hurdles and compliance costs associated with pharmaceutical product commercialization in the U.S., which can impact operational expenses and market access.

What Are the Growth Opportunities for BFRIW?

• One significant growth opportunity for Biofrontera Inc. lies in expanding the market penetration of Ameluz within the existing indication for mild-to-moderate actinic keratosis on the face and scalp. The actinic keratosis market is substantial and growing, driven by an aging population and increased awareness of sun damage. By enhancing sales and marketing efforts, increasing physician education on the benefits of photodynamic therapy with Ameluz and the BF-RhodoLED lamp series, and targeting a broader network of dermatological clinics, Biofrontera can capture a larger share of this established market. The continuous need for effective, non-invasive treatments for precancerous lesions provides a sustained demand for such therapies.
• Another growth avenue involves exploring and pursuing new indications or expanded use cases for Ameluz. While currently approved for actinic keratosis, the underlying mechanism of photodynamic therapy has potential applications in other dermatological conditions, including certain types of skin cancer or other precancerous lesions. Successfully navigating regulatory processes for additional indications could significantly broaden Ameluz's market appeal and revenue potential. Such expansion would leverage the existing product and infrastructure, potentially offering a more cost-effective path to growth compared to developing entirely new compounds, and could open new patient populations within the next 3-5 years.
• The commercialization of Xepi, a topical treatment for impetigo, presents a distinct growth opportunity. Impetigo is a common bacterial skin infection, particularly prevalent in children, ensuring a consistent patient base. Biofrontera Inc. can capitalize on this by increasing awareness among pediatricians and general practitioners, in addition to dermatologists, about Xepi's efficacy and non-fluorinated quinolone profile. Expanding market share in the topical antibiotic segment for impetigo, through targeted promotional activities and demonstrating clinical advantages, could drive incremental revenue growth. This market is relatively stable, providing a reliable source of revenue as the company aims for broader adoption.
• Leveraging the BF-RhodoLED lamp series beyond its current application with Ameluz for actinic keratosis offers a strategic growth pathway. The lamp series represents a significant capital investment for clinics and could potentially be utilized with other photosensitizers or for different photodynamic therapy applications, should Biofrontera Inc. develop or acquire additional compatible treatments. Exploring partnerships or licensing agreements for the lamp technology with other pharmaceutical companies developing PDT agents could create new revenue streams. This approach maximizes the utility of existing assets and positions Biofrontera as a key player in PDT technology, potentially within a 5-year horizon.
• Strategic partnerships or targeted acquisitions within the dermatology space represent a long-term growth opportunity. By collaborating with or acquiring companies that have complementary product portfolios, pipeline assets, or specialized technologies, Biofrontera Inc. could diversify its offerings, expand its market reach, and gain access to new intellectual property. Such strategic moves could accelerate product development, enhance commercial capabilities, or enter new therapeutic areas within dermatology, thereby strengthening its competitive position and mitigating reliance on its current product lineup. This strategy would require significant capital but could unlock substantial value over a 5-10 year timeframe.

What Threats Does BFRIW Face?

• Intense competition from other dermatological treatment providers and pharmaceutical companies.
• Regulatory changes or delays affecting product approvals or market access.
• Patent expirations or emergence of generic/biosimilar alternatives for its products.
• Dependence on third-party manufacturing or distribution channels.
• Economic downturns impacting healthcare spending and patient access to specialized treatments.

What Are BFRIW's Competitive Advantages?

• Proprietary Ameluz drug and BF-RhodoLED lamp series for photodynamic therapy, offering a specific treatment modality.
• Regulatory approvals (e.g., for Ameluz and Xepi) in the U.S. market, creating barriers to entry for new competitors.
• Specialization in targeted dermatological conditions, allowing for focused expertise and market penetration.
• Established commercial infrastructure and relationships within the U.S. dermatology community.

What Does BFRIW Do?

Biofrontera Inc. is a biopharmaceutical firm established in 2015, headquartered in Woburn, Massachusetts, with a focused mission on the commercialization of pharmaceutical solutions for various skin-related ailments across the United States. The company's core product offering revolves around Ameluz, a prescription drug specifically designed for use in conjunction with the BF-RhodoLED lamp series for photodynamic therapy (PDT). This innovative treatment modality is indicated for the management of mild-to-moderate actinic keratosis, a common precancerous skin lesion, on both localized areas and broader regions of the face and scalp. Ameluz, as a photosensitizer, works by making target cells more susceptible to light, which, when activated by the BF-RhodoLED lamp, selectively destroys the abnormal cells. This approach offers a non-invasive option for patients. In addition to its flagship PDT system, Biofrontera Inc. also markets Xepi, a topical, non-fluorinated quinolone. Xepi's mechanism of action involves inhibiting bacterial growth, making it an effective treatment for impetigo, a common bacterial skin infection. The company's strategic focus is on leveraging its commercial infrastructure to maximize the reach and adoption of these specialized dermatological therapies within the U.S. market. With 92 employees, Biofrontera Inc. aims to serve the needs of dermatologists and their patients by providing targeted, effective treatments for prevalent skin conditions, thereby carving out a niche in the competitive specialty and generic drug manufacturing industry.

What Products and Services Does BFRIW Offer?

• Commercializes pharmaceutical solutions for skin-related ailments across the United States.
• Offers Ameluz, a prescription drug used with the BF-RhodoLED lamp series for photodynamic therapy.
• Provides treatment for mild-to-moderate actinic keratosis on the face and scalp using Ameluz.
• Markets Xepi, a topical, non-fluorinated quinolone for treating impetigo.
• Focuses on biopharmaceutical products for dermatology.
• Engages in the development and commercialization of dermatological products, primarily for skin cancer treatment.

How Does BFRIW Make Money?

• Generates revenue through the sale of prescription drugs like Ameluz and Xepi to healthcare providers and pharmacies.
• Sells or leases the BF-RhodoLED lamp series, which is integral to the Ameluz photodynamic therapy treatment.
• Relies on a commercialization strategy focused on the U.S. market for its specialized dermatological products.
• Aims for profitability through high gross margins on its pharmaceutical products, despite current overall losses.

What Industry Does BFRIW Operate In?

Biofrontera Inc. operates within the highly specialized and competitive U.S. dermatological biopharmaceutical industry, focusing on treatments for skin-related ailments. The market for dermatological drugs is characterized by a growing prevalence of skin conditions, including actinic keratosis and bacterial infections like impetigo, driven by factors such as an aging population, increased sun exposure, and evolving environmental factors. Biofrontera Inc. positions itself by offering targeted solutions like Ameluz for photodynamic therapy, which competes with other topical and systemic treatments for actinic keratosis, and Xepi for impetigo, competing with other topical antibiotics. The industry also sees ongoing innovation in drug delivery systems and treatment modalities. While the market for specialty drugs is often lucrative due to higher pricing power, it also demands significant investment in R&D, regulatory compliance, and commercialization infrastructure. Biofrontera's focus on established products in specific niches allows it to carve out a presence within this dynamic landscape.

Who Are BFRIW's Key Customers?

• Dermatologists and dermatological clinics in the United States.
• Healthcare professionals treating actinic keratosis and impetigo.
• Patients prescribed Ameluz for actinic keratosis.
• Patients prescribed Xepi for impetigo.
• Pharmacies and distributors that stock specialized dermatological medications.

Company Profile

Biofrontera Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Hermann Luebbert. BFRIW has traded publicly since 2021.

Biofrontera Inc. Financial Trajectory

Biofrontera Inc. (BFRIW) reported $12.0M in revenue for Q2 2026, reflecting 19.0% growth compared to the prior quarter. The company recorded a net loss of $604K, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BFRIW averaged $-0.15 in diluted EPS.

How Biofrontera Inc. Is Valued

Biofrontera Inc. carries a market capitalization of $16.7M, placing it in the micro-cap category. Relative to its peer group, BFRIW's quantitative score of 47/100 is below the peer average of 62/100.

Key Financial Metrics

Return on assets is -26.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -41.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -33.3%, the inverse of the P/E and a quick read on earnings relative to price.

Biofrontera Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.34 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Biofrontera Inc. revenue of about $45.6M for fiscal 2026, with EPS near $-0.23.

Over the past six months, Biofrontera Inc. insiders filed 14 SEC Form 4 transactions — 2 sales and 12 purchases. On net that is roughly 555K shares acquired (about $286K) — insiders putting money in tends to read as conviction.

BFRIW Financials

BFRIW Latest News

No recent news available for BFRIW.

BFRIW Analyst Consensus

BFRIW MoonshotScore

BFRIW Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources